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Chinese hamster ovary (CHO) cells are the most common mammalian cell line used for
producing bio-therapeutic proteins and serve as the expression system of choice for
most best-selling biologics. Although these cells are widely used, the genetic bases
underlying desirable phenotypes remain difficult to elucidate. CRISPR/Cas9-mediated
genome engineering has proven effective in CHO cells in smaller formats, yet rational
target  identification  on  a  high  throughput  level  remains  a  bottleneck.  CRISPR
screening methods have been used in human cancer cell lines to identify novel
therapeutic targets but their efficacy in CHO cells for identifying targets for
improved cell behavior has not yet been demonstrated. Here we develop a CRISPR/Cas9
knockout screening platform in CHO cells, enabling high throughput target discovery
under diverse selection pressures. 
We have designed a library comprising ~16,000 gRNAs against ~2500 metabolic targets
using the CHO-K1 genome and genome scale model of CHO cell metabolism. The library
was used to generate a pool of cells each expressing a single gRNA. As a proof of
concept, we have independently subjected the pool of cells to strong and weak
selection pressures to identify genes that influence cell growth and product quality.
We will discuss the unique challenges encountered in translating CRISPR/Cas9 screens
to CHO cells – including technical optimizations during generation and validation of
the library that are necessary to ensure the accurate identification of targets.
Furthermore,  we  will  present  preliminary  results  from  our  initial  selection
experiments. 
 
